Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma

References

• Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317–322. doi:10.1001/jamaoto.2014.124557566
   PubMed Web of Science ®Google Scholar
• Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212. doi:10.1155/2013/96521223737785
   PubMedGoogle Scholar
• Yu GP, Li JC, Branovan D, McCormick S, Schantz SP. Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid. 2010;20(5):465–473. doi:10.1089/thy.2008.028120384488
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.CAN-14-015524840647
   PubMed Web of Science ®Google Scholar
• ACS. American Cancer Society: cancer facts and figures. 2016;2016.
   Google Scholar
• Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see commetns]. Cancer. 1998;83(12):2638–2648. 9874472
   PubMed Web of Science ®Google Scholar
• Oh CM, Won YJ, Jung KW, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat. 2016;48(2):436–450. doi:10.4143/crt.2016.08926987395
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109–142. doi:10.1089/thy.2006.16.10916420177
   PubMed Web of Science ®Google Scholar
• Grant CS. Recurrence of papillary thyroid cancer after optimized surgery. Gland Surg. 2015;4(1):52–62. doi:10.3978/j.issn.2227-684X.2014.12.0625713780
   PubMed Web of Science ®Google Scholar
• Carneiro RM, Carneiro BA, Agulnik M, Kopp PA, Giles FJ. Targeted therapies in advanced differentiated thyroid cancer. Cancer Treat Rev. 2015;41(8):690–698. doi:10.1016/j.ctrv.2015.06.00226105190
   PubMed Web of Science ®Google Scholar
• Kojic KL, Kojic SL, Wiseman SM. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies. Expert Rev Anticancer Ther. 2012;12(3):345–357. doi:10.1586/era.12.822369326
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Sherman SI. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid. 2009;19(12):1393–1400. doi:10.1089/thy.2009.160320001721
   PubMed Web of Science ®Google Scholar
• Jose C, Bellance N, Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor’s dilemma? Biochimica et biophysica acta. Jun. 2011;1807(6):552–561.
   Google Scholar
• Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nature Rev Cancer. 2011;11(5):325–337. doi:10.1038/nrc303821508971
   PubMed Web of Science ®Google Scholar
• Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Annals oncol. 2016;27(4):599–608. doi:10.1093/annonc/mdw013
   PubMed Web of Science ®Google Scholar
• Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324(5924):261–265. doi:10.1126/science.117094419359588
   PubMed Web of Science ®Google Scholar
• Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2):339–344. doi:10.1084/jem.2009250620142433
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2010;465(7300):966. doi:10.1038/nature0913220559394
   PubMed Web of Science ®Google Scholar
• Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225–234. doi:10.1016/j.ccr.2010.01.02020171147
   PubMed Web of Science ®Google Scholar
• Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474–478. doi:10.1038/nature1086022343901
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17–30. doi:10.1016/j.ccr.2010.12.01421251613
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773. doi:10.1056/NEJMoa080871019228619
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J clin oncol. 2010;28(14):2348–2355. doi:10.1200/JCO.2009.27.373020368543
   PubMed Web of Science ®Google Scholar
• Fujii T, Khawaja MR, DiNardo CD, Atkins JT, Janku F. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med. 2016;21(117):373–380. 27355333
   PubMed Web of Science ®Google Scholar
• Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun. 2010;393(3):555–559. doi:10.1016/j.bbrc.2010.02.09520171178
   PubMed Web of Science ®Google Scholar
• Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics. 2004;84(6):1014–1020. doi:10.1016/j.ygeno.2004.08.01015533718
   PubMed Web of Science ®Google Scholar
• Guirguis A, Elishaev E, Oh SH, Tseng GC, Zorn K, DeLoia JA. Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary. Gynecol Oncol. 2008;108(2):370–376. doi:10.1016/j.ygyno.2007.10.00818083218
   PubMed Web of Science ®Google Scholar
• Wang WZ, Guo X, Duan C, et al. Comparative analysis of gene expression profiles between the normal human cartilage and the one with endemic osteoarthritis. Osteoarthritis Cartilage. 2009;17(1):83–90. doi:10.1016/j.joca.2008.05.00818579416
   PubMed Web of Science ®Google Scholar
• Tian GY, Zang SF, Wang L, Luo Y, Shi JP, Lou GQ. Isocitrate dehydrogenase 2 suppresses the invasion of hepatocellular carcinoma cells via matrix metalloproteinase 9. Cell Physiol Biochem. 2015;37(6):2405–2414. doi:10.1159/00043859326646705
   PubMedGoogle Scholar
• Wu D. Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7. Tumour Biol. 2016;37(4):5225–5230. doi:10.1007/s13277-015-4358-226553362
   PubMedGoogle Scholar
• Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 2009;30(1):7–11. doi:10.1002/humu.2093719117336
   PubMed Web of Science ®Google Scholar
• Chen X, Xu W, Wang C, et al. The clinical significance of isocitrate dehydrogenase 2 in esophageal squamous cell carcinoma. Am J Cancer Res. 2017;7(3):700–714. 28401022
   PubMed Web of Science ®Google Scholar
• Liu WR, Tian MX, Jin L, et al. High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma. J Exp Clin Cancer Res. 2014;33:32. doi:10.1186/1756-9966-33-3224716838
   PubMed Web of Science ®Google Scholar
• Lv Q, Xing S, Li Z, et al. Altered expression levels of IDH2 are involved in the development of colon cancer. Exp Ther Med. 2012;4(5):801–806. doi:10.3892/etm.2012.67623226729
   PubMed Web of Science ®Google Scholar
• Memon AA, Chang JW, Oh BR, Yoo YJ. Identification of differentially expressed proteins during human urinary bladder cancer progression. Cancer Detect Prev. 2005;29(3):249–255. doi:10.1016/j.cdp.2005.01.00215936593
   PubMedGoogle Scholar
• Wise DR, Ward PS, Shay JE, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA. 2011;108(49):19611–19616. doi:10.1073/pnas.111777310822106302
   PubMed Web of Science ®Google Scholar
• Nakamura H. Thioredoxin and its related molecules: update 2005. Antioxid Redox Signal. 2005;7(5–6):823–828. doi:10.1089/ars.2005.7.82315890030
   PubMed Web of Science ®Google Scholar
• Avery AM, Willetts SA, Avery SV. Genetic dissection of the phospholipid hydroperoxidase activity of yeast gpx3 reveals its functional importance. J Biol Chem. 2004;279(45):46652–46658. doi:10.1074/jbc.M40834020015337745
   PubMed Web of Science ®Google Scholar
• Lu J, Holmgren A. Thioredoxin system in cell death progression. Antioxid Redox Signal. 2012;17(12):1738–1747. doi:10.1089/ars.2012.465022530689
   PubMed Web of Science ®Google Scholar
• Kim S, Kim SY, Ku HJ, et al. Suppression of tumorigenesis in mitochondrial NADP(+)-dependent isocitrate dehydrogenase knock-out mice. Biochim Biophys Acta. 2014;1842(2):135–143. doi:10.1016/j.bbadis.2013.11.00824240089
   PubMed Web of Science ®Google Scholar
• Benhar M, Shytaj IL, Stamler JS, Savarino A. Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. J Clin Invest. 2016;126(5):1630–1639. doi:10.1172/JCI8533927135880
   PubMed Web of Science ®Google Scholar
• Geisbrecht BV, Gould SJ. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem. 1999;274(43):30527–30533. 10521434
   PubMed Web of Science ®Google Scholar